<DOC>
	<DOCNO>NCT00435578</DOCNO>
	<brief_summary>The primary objective study : 1 . To evaluate efficacy glufosfamide subject extensive recurrent sensitive small cell lung cancer ( SCLC ) measure objective response rate 2 . To evaluate safety glufosfamide subject extensive recurrent sensitive SCLC The secondary objective : 1 . To evaluate efficacy glufosfamide subject extensive recurrent sensitive SCLC measure duration response , progression-free survival overall survival 2 . To evaluate pharmacokinetics glufosfamide isophosphoramide mustard ( IPM ) The exploratory objective trial : 1 . To evaluate effect glufosfamide lung cancer symptoms 2 . To evaluate role tumor cell glucose transporter expression efficacy glufosfamide</brief_summary>
	<brief_title>Safety Efficacy Study Glufosfamide Patients With Recurrent Sensitive Small Cell Lung Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/IEC Documented extensive SCLC progression occur least 60 day completion firstline therapy ( sensitive disease ) Measurable disease RECIST criterion ( least one target lesion ; target lesion may receive radiotherapy within 6 week study start ) A minimum 21 day prior radiation therapy , immunotherapy , antitumor therapy study entry Recovered reversible toxicity prior therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 0 , 1 , 2 Hemoglobin ≥ 9.0 g/dL , ANC ≥ 1,500/µL , platelet ≥ 100,000/µL Total bilirubin ≤ 1.5fold ULN AST/ALT ≤ 2.5fold ULN ( ≤ 5fold ULN liver metastasis ) Creatinine clearance ≥ 60 mL/min ( calculate CockcroftGault formula ) All woman childbearing potential men must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) entry study 6 month last dose More one previous chemotherapy regimen Concomitant plan hormonal therapy , radiation therapy , biologic therapy , chemotherapy systemic antitumor therapy SCLC protocol therapy Limited stage SCLC ( define confine one hemithorax include ipsilateral supraclavicular lymph node exclude pleural effusion ) Symptomatic brain metastasis require corticosteroid Active clinically significant infection require antibiotic Known HIV positive active hepatitis B C Recent ( one year ) history symptom cardiovascular disease ( NYHA Class 2 , 3 , 4 ) , particularly coronary artery disease , arrhythmias conduction defect risk cardiovascular instability , uncontrolled hypertension , clinically significant pericardial effusion , congestive heart failure , stroke Other active malignancy ( treat nonmelanoma skin cancer treat situ cancer ) within past 5 year Major surgery within 28 day start study treatment , without complete recovery Females pregnant breastfeed Participation investigational drug device study within 28 day first day dose study Concomitant disease condition could interfere conduct study , , opinion investigator , could pose unacceptable risk subject study . Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Recurrent Sensitive Small-Cell Lung Cancer</keyword>
</DOC>